Literature DB >> 27325776

Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation.

Christian J Braun1, Peter M Bruno1, Max A Horlbeck2, Luke A Gilbert2, Jonathan S Weissman2, Michael T Hemann3.   

Abstract

Targeted transcriptional regulation is a powerful tool to study genetic mediators of cellular behavior. Here, we show that catalytically dead Cas9 (dCas9) targeted to genomic regions upstream or downstream of the transcription start site allows for specific and sustainable gene-expression level alterations in tumor cells in vitro and in syngeneic immune-competent mouse models. We used this approach for a high-coverage pooled gene-activation screen in vivo and discovered previously unidentified modulators of tumor growth and therapeutic response. Moreover, by using dCas9 linked to an activation domain, we can either enhance or suppress target gene expression simply by changing the genetic location of dCas9 binding relative to the transcription start site. We demonstrate that these directed changes in gene-transcription levels occur with minimal off-target effects. Our findings highlight the use of dCas9-mediated transcriptional regulation as a versatile tool to reproducibly interrogate tumor phenotypes in vivo.

Entities:  

Keywords:  CRISPR; cancer genetics; cancer models; cancer therapeutic resistance; gene regulation

Mesh:

Substances:

Year:  2016        PMID: 27325776      PMCID: PMC4941480          DOI: 10.1073/pnas.1600582113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  59 in total

1.  Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells.

Authors:  Xuebing Wu; David A Scott; Andrea J Kriz; Anthony C Chiu; Patrick D Hsu; Daniel B Dadon; Albert W Cheng; Alexandro E Trevino; Silvana Konermann; Sidi Chen; Rudolf Jaenisch; Feng Zhang; Phillip A Sharp
Journal:  Nat Biotechnol       Date:  2014-04-20       Impact factor: 54.908

2.  High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells.

Authors:  Yuexin Zhou; Shiyou Zhu; Changzu Cai; Pengfei Yuan; Chunmei Li; Yanyi Huang; Wensheng Wei
Journal:  Nature       Date:  2014-04-09       Impact factor: 49.962

3.  CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.

Authors:  G Zoppoli; S Solier; W C Reinhold; H Liu; J W Connelly; A Monks; R H Shoemaker; O D Abaan; S R Davis; P S Meltzer; J H Doroshow; Y Pommier
Journal:  Oncogene       Date:  2011-07-18       Impact factor: 9.867

4.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

5.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

6.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

7.  Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.

Authors:  Richard T Williams; Martine F Roussel; Charles J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-17       Impact factor: 11.205

Review 8.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

Authors:  Thomas Gaj; Charles A Gersbach; Carlos F Barbas
Journal:  Trends Biotechnol       Date:  2013-05-09       Impact factor: 19.536

9.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering.

Authors:  Prashant Mali; John Aach; P Benjamin Stranges; Kevin M Esvelt; Mark Moosburner; Sriram Kosuri; Luhan Yang; George M Church
Journal:  Nat Biotechnol       Date:  2013-08-01       Impact factor: 54.908

10.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors.

Authors:  Pablo Perez-Pinera; D Dewran Kocak; Christopher M Vockley; Andrew F Adler; Ami M Kabadi; Lauren R Polstein; Pratiksha I Thakore; Katherine A Glass; David G Ousterout; Kam W Leong; Farshid Guilak; Gregory E Crawford; Timothy E Reddy; Charles A Gersbach
Journal:  Nat Methods       Date:  2013-07-25       Impact factor: 28.547

View more
  34 in total

1.  CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells.

Authors:  S John Liu; Max A Horlbeck; Seung Woo Cho; Harjus S Birk; Martina Malatesta; Daniel He; Frank J Attenello; Jacqueline E Villalta; Min Y Cho; Yuwen Chen; Mohammad A Mandegar; Michael P Olvera; Luke A Gilbert; Bruce R Conklin; Howard Y Chang; Jonathan S Weissman; Daniel A Lim
Journal:  Science       Date:  2016-12-15       Impact factor: 47.728

Review 2.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

Review 3.  Live-Animal Epigenome Editing: Convergence of Novel Techniques.

Authors:  J Antonio Gomez; Ulrika Beitnere; David J Segal
Journal:  Trends Genet       Date:  2019-05-22       Impact factor: 11.639

Review 4.  Am I ready for CRISPR? A user's guide to genetic screens.

Authors:  John G Doench
Journal:  Nat Rev Genet       Date:  2017-12-04       Impact factor: 53.242

5.  Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform.

Authors:  Kirk J Wangensteen; Yue J Wang; Zhixun Dou; Amber W Wang; Elham Mosleh-Shirazi; Max A Horlbeck; Luke A Gilbert; Jonathan S Weissman; Shelley L Berger; Klaus H Kaestner
Journal:  Hepatology       Date:  2018-05-14       Impact factor: 17.425

Review 6.  Cancer CRISPR Screens In Vivo.

Authors:  Ryan D Chow; Sidi Chen
Journal:  Trends Cancer       Date:  2018-03-30

Review 7.  Cancer induction and suppression with transcriptional control and epigenome editing technologies.

Authors:  Shota Nakade; Takashi Yamamoto; Tetsushi Sakuma
Journal:  J Hum Genet       Date:  2017-11-14       Impact factor: 3.172

Review 8.  New breeding technique "genome editing" for crop improvement: applications, potentials and challenges.

Authors:  Supriya B Aglawe; Kalyani M Barbadikar; Satendra K Mangrauthia; M Sheshu Madhav
Journal:  3 Biotech       Date:  2018-07-23       Impact factor: 2.406

Review 9.  In vivo epigenome editing and transcriptional modulation using CRISPR technology.

Authors:  Cia-Hin Lau; Yousin Suh
Journal:  Transgenic Res       Date:  2018-10-04       Impact factor: 2.788

10.  Proteomic Profiling of the ECM of Xenograft Breast Cancer Metastases in Different Organs Reveals Distinct Metastatic Niches.

Authors:  Jess D Hebert; Samuel A Myers; Alexandra Naba; Genevieve Abbruzzese; John M Lamar; Steven A Carr; Richard O Hynes
Journal:  Cancer Res       Date:  2020-02-04       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.